Upstream Bio (UPB) Q4 2025 earnings summary

Executive summary

• Announced a Phase 3 development strategy for verekitug, targeting severe asthma and CRSwNP with a high-dose quarterly regimen for broad patient populations.

• Positive top-line results from Phase 2 VALIANT trial in severe asthma showed significant improvements in exacerbations and lung function.

• Additional analyses from Phase 2 VIBRANT trial in CRSwNP reinforced efficacy and safety, supporting continued development.

• Ongoing Phase 2 VENTURE trial in COPD is over 60% enrolled, with endpoints potentially supporting product approval.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $341.5 million as of December 31, 2025, expected to fund operations through 2027.

• Research and development expenses for Q4 2025 were $40.2 million, up from $21.8 million in Q4 2024, mainly due to increased clinical and manufacturing costs.

• General and administrative expenses for Q4 2025 were $6.7 million, up from $5.2 million in Q4 2024, driven by higher professional fees and personnel costs.

• Net loss for Q4 2025 was $42.5 million, compared to $21.2 million in Q4 2024, reflecting increased R&D spending.

• Collaboration revenue for Q4 2025 was $668,000, compared to $613,000 in Q4 2024.

Outlook and guidance

• Plans to initiate Phase 3 dosing in both severe asthma and CRSwNP in Q1 2027, pending regulatory alignment.

• Market research supports a focus on high efficacy and quarterly dosing convenience for commercial success.

• Cash runway expected to support planned operations through 2027.